Compare IPCA Labs with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUVEN LIFE SCIENCES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUVEN LIFE SCIENCES IPCA LABS/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 23.2 -97.2 - View Chart
P/BV x 8.3 1.5 544.9% View Chart
Dividend Yield % 0.1 1.5 9.7%  

Financials

 IPCA LABS   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    IPCA LABS
Mar-19
SUVEN LIFE SCIENCES
Mar-19
IPCA LABS/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,042338 308.6%   
Low Rs590169 348.3%   
Sales per share (Unadj.) Rs298.652.1 572.9%  
Earnings per share (Unadj.) Rs35.06.8 512.4%  
Cash flow per share (Unadj.) Rs49.48.6 576.9%  
Dividends per share (Unadj.) Rs3.001.50 200.0%  
Dividend yield (eoy) %0.40.6 62.1%  
Book value per share (Unadj.) Rs247.165.3 378.5%  
Shares outstanding (eoy) m126.35127.28 99.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.74.9 56.2%   
Avg P/E ratio x23.337.1 62.8%  
P/CF ratio (eoy) x16.529.6 55.8%  
Price / Book Value ratio x3.33.9 85.0%  
Dividend payout %8.622.0 39.0%   
Avg Mkt Cap Rs m103,10832,272 319.5%   
No. of employees `00013.41.1 1,242.3%   
Total wages/salary Rs m7,874661 1,190.9%   
Avg. sales/employee Rs Th2,807.06,132.2 45.8%   
Avg. wages/employee Rs Th585.8611.1 95.9%   
Avg. net profit/employee Rs Th329.0803.5 40.9%   
INCOME DATA
Net Sales Rs m37,7326,635 568.7%  
Other income Rs m577242 238.1%   
Total revenues Rs m38,3096,877 557.0%   
Gross profit Rs m6,9011,604 430.2%  
Depreciation Rs m1,824221 823.9%   
Interest Rs m18938 500.5%   
Profit before tax Rs m5,4651,587 344.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042718 145.2%   
Profit after tax Rs m4,422869 508.6%  
Gross profit margin %18.324.2 75.6%  
Effective tax rate %19.145.2 42.2%   
Net profit margin %11.713.1 89.4%  
BALANCE SHEET DATA
Current assets Rs m23,7786,232 381.5%   
Current liabilities Rs m10,9751,490 736.5%   
Net working cap to sales %33.971.5 47.5%  
Current ratio x2.24.2 51.8%  
Inventory Days Days10486 120.0%  
Debtors Days Days6683 79.8%  
Net fixed assets Rs m20,3684,043 503.7%   
Share capital Rs m253127 198.5%   
"Free" reserves Rs m30,9718,183 378.5%   
Net worth Rs m31,2248,310 375.7%   
Long term debt Rs m1,40918 7,912.9%   
Total assets Rs m45,50710,389 438.0%  
Interest coverage x30.043.1 69.5%   
Debt to equity ratio x00 2,105.9%  
Sales to assets ratio x0.80.6 129.8%   
Return on assets %10.18.7 116.0%  
Return on equity %14.210.5 135.4%  
Return on capital %17.319.5 88.8%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3085,622 307.9%   
Fx outflow Rs m6,2661,799 348.2%   
Net fx Rs m11,0423,822 288.9%   
CASH FLOW
From Operations Rs m4,923356 1,384.8%  
From Investments Rs m-1,563-279 561.1%  
From Financial Activity Rs m-1,832-225 813.9%  
Net Cashflow Rs m1,528-148 -1,030.8%  

Share Holding

Indian Promoters % 45.9 63.4 72.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 36.5 47.7%  
Shareholders   36,892 37,287 98.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 7, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - NATCO PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS